Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
NCT01825395 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2021-10-06
Summary
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
Conditions
- Lambert Eaton Myasthenic Syndrome
Interventions
- DRUG
-
3, 4-Diaminopyridine
Sponsors & Collaborators
-
University of Colorado, Denver
lead OTHER
Principal Investigators
-
Steven P Ringel, MD · University of Colorado, Denver
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
NCT01373333 ·Status: NO_LONGER_AVAILABLE
-
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
NCT02090725 ·Status: TERMINATED ·Phase: PHASE2
-
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
NCT02012933 ·Status: NO_LONGER_AVAILABLE
-
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
NCT01378546 ·Status: NO_LONGER_AVAILABLE
-
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
NCT01377922 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Use of 3,4-Diaminopyridine
NCT01765140 ·Status: NO_LONGER_AVAILABLE
-
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
NCT02970162 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
NCT03062631 ·Status: NO_LONGER_AVAILABLE
-
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
NCT02189720 ·Status: APPROVED_FOR_MARKETING
-
4-Aminopyridine in Episodic Ataxia Type 2
NCT01543750 ·Status: WITHDRAWN ·Phase: PHASE2
-
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
NCT02562066 ·Status: COMPLETED ·Phase: PHASE3
-
Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)
NCT02045667 ·Status: COMPLETED ·Phase: PHASE2
-
Dextromethorphan to Treat Patients With Voice Spasms
NCT00055549 ·Status: COMPLETED ·Phase: PHASE1
-
Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA
NCT05544058 ·Status: COMPLETED
-
Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
NCT00135993 ·Status: COMPLETED ·Phase: PHASE3
-
Study of NMDA Antagonists and Neuropathic Pain
NCT01602185 ·Status: COMPLETED ·Phase: PHASE2
-
Dimethyl Fumarate in Adrenomyeloneuropathy
NCT06513533 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy
NCT00481013 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
NCT04616807 ·Status: ACTIVE_NOT_RECRUITING
-
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
NCT01645787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
NCT01468350 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
NCT04492956 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study of Dexpramipexole in ALS
NCT01281189 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
NCT03218969 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
NCT03728933 ·Status: TERMINATED ·Phase: PHASE3